亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

彭布罗利珠单抗 医学 肺癌 内科学 危险系数 肿瘤科 化疗 胃肠病学 免疫疗法 癌症 置信区间
作者
Martin Reck,Delvys Rodríguez‐Abreu,Andrew Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinéad Cuffe,Mary O’Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma Rangwala,Julie R. Brahmer
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:375 (19): 1823-1833 被引量:10148
标识
DOI:10.1056/nejmoa1606774
摘要

BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3 trial, we randomly assigned 305 patients who had previously untreated advanced NSCLC with PD-L1 expression on at least 50% of tumor cells and no sensitizing mutation of the epidermal growth factor receptor gene or translocation of the anaplastic lymphoma kinase gene to receive either pembrolizumab (at a fixed dose of 200 mg every 3 weeks) or the investigator's choice of platinum-based chemotherapy. Crossover from the chemotherapy group to the pembrolizumab group was permitted in the event of disease progression. The primary end point, progression-free survival, was assessed by means of blinded, independent, central radiologic review. Secondary end points were overall survival, objective response rate, and safety. RESULTS: Median progression-free survival was 10.3 months (95% confidence interval [CI], 6.7 to not reached) in the pembrolizumab group versus 6.0 months (95% CI, 4.2 to 6.2) in the chemotherapy group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.37 to 0.68; P<0.001). The estimated rate of overall survival at 6 months was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy group (hazard ratio for death, 0.60; 95% CI, 0.41 to 0.89; P=0.005). The response rate was higher in the pembrolizumab group than in the chemotherapy group (44.8% vs. 27.8%), the median duration of response was longer (not reached [range, 1.9+ to 14.5+ months] vs. 6.3 months [range, 2.1+ to 12.6+]), and treatment-related adverse events of any grade were less frequent (occurring in 73.4% vs. 90.0% of patients), as were grade 3, 4, or 5 treatment-related adverse events (26.6% vs. 53.3%). CONCLUSIONS: In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab was associated with significantly longer progression-free and overall survival and with fewer adverse events than was platinum-based chemotherapy. (Funded by Merck; KEYNOTE-024 ClinicalTrials.gov number, NCT02142738 .).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
orixero的应助被簡簡單單采纳,获得10
2秒前
尊敬康乃馨完成签到,获得积分10
43秒前
52秒前
簡簡單單发布了新的文献求助10
57秒前
簡簡單單完成签到,获得积分10
1分钟前
迷人啤酒完成签到,获得积分10
1分钟前
1分钟前
wickedjon完成签到,获得积分10
1分钟前
11kk发布了新的文献求助30
1分钟前
freelancerart完成签到,获得积分10
1分钟前
共享精神的应助被11kk采纳,获得10
1分钟前
清爽小凡完成签到,获得积分10
1分钟前
anugraphics完成签到,获得积分10
1分钟前
hamburger完成签到,获得积分10
1分钟前
内向的小丸子完成签到,获得积分10
1分钟前
机智的白卉的应助被u501249采纳,获得30
1分钟前
Lucas的应助被u766482采纳,获得30
2分钟前
靓丽的小懒虫完成签到,获得积分10
2分钟前
科研通AI65的应助被2589采纳,获得10
2分钟前
给苏打饼干扎眼完成签到,获得积分10
2分钟前
zhangr完成签到 ,获得积分10
2分钟前
搜集达人的应助被ny960采纳,获得10
2分钟前
完美飞凤完成签到,获得积分10
2分钟前
2分钟前
2589发布了新的文献求助10
2分钟前
3分钟前
n01W97的应助被科研通管家采纳,获得20
3分钟前
ny960发布了新的文献求助10
3分钟前
UU有点皮完成签到 ,获得积分10
3分钟前
斯文败类的应助被2589采纳,获得10
3分钟前
histamin完成签到,获得积分10
3分钟前
震动的醉蓝完成签到,获得积分10
3分钟前
ny960完成签到,获得积分10
3分钟前
舒心谷菱完成签到,获得积分10
4分钟前
4分钟前
4分钟前
cen发布了新的文献求助10
4分钟前
11kk发布了新的文献求助10
4分钟前
隐形曼青的应助被11kk采纳,获得10
4分钟前
和谐的山水完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185196
求助须知:如何正确求助?哪些是违规求助? 9574060
关于积分的说明 21834179
捐赠科研通 7782698
什么是DOI,文献DOI怎么找? 3434531
关于科研通互助平台的介绍 2558786
邀请新用户注册赠送积分活动 2481218